CCA
XERS icon

Childress Capital Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Childress Capital Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,375
Closed -$7K – 974
2020
Q4 		$7K Buy
+1,375
New +$6.88K ﹤0.01% 674

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Childress Capital Advisors's XERS Position: Q1 2021 in Review

Childress Capital Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2021, closing a stake of 1,375 shares — an estimated $7K sold.

Childress Capital Advisors first reported a position in XERS in Q4 2020 and held it in 1 quarter. The position peaked at $7K in Q4 2020. 103 funds tracked by Wall St. Rank hold XERS as of Q1 2021.

  • Childress Capital Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 1,375 Xeris Biopharma Holdings shares in Q1 2021, an estimated $7K.
  • Childress Capital Advisors first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Xeris Biopharma Holdings position peaked at $7K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.